Observational studyPloS one2026
COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaintenance hemodialysis patients experience higher morbidity and mortality from COVID-19, partly due to comorbidities like diabetes and cardiovascular disease. However, kidney disease-related metabolic processes may also contribute.
methodsIn this prospective, multi-center, observational study, we analyzed 201 routine serum samples from 30 hemodialysis patients (average age 59.2 ± 13.3 years, 57% male) with confirmed COVID-19, collected from 60 days before and 60 days after diagnosis. Untargeted liquid chromatography/mass spectrometry was used to profile metabolites. Linear and semi-parametric mixed-effects models were applied to assess changes across four phases: baseline (-60 to -15 days), putative incubation period (PIP; -14-0 days), acute (1-14 days), and post-COVID (15-60 days). Because infection and symptoms may vary across individuals, -14-0 days were used as an approximate pre-diagnosis window rather than a precise incubation interval.
resultsAmong 417 metabolomic features, 10 showed significant changes between baseline and PIP. Two metabolites, α-guanidinoglutaric acid and N-acetylneuraminic acid, were identified through library matching, while the remainder were characterized by mass and retention time. Temporal analysis revealed both transient metabolic shifts, which returned to baseline, and persistent changes, which remained altered post-COVID.
conclusionsThese findings suggest that early metabolic changes before COVID-19 diagnosis may be detected in routine serum samples, offering opportunities to develop predictive models for early detection. Identifying these unique metabolomics fingerprints could improve personalized surveillance strategies and enhance understanding of COVID-19's impact on hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.